Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
Other Sizes |
|
ln Vitro |
In T47D cells, SUN B8155 (1-1000 μM; 1 hour) increases intracellular cAMP production in a concentration-dependent manner; at the highest dose, the concentration of produced cAMP increased by about 42-fold. Additionally, SUN B8155 promotes the production of cAMP in the rat osteogenic sarcoma-derived cell line UMR106-06[1]. While SUN B8155 completely promotes cAMP formation in CHO/hCTR cells in a concentration-dependent manner with an EC50 of 21 μM, it does not stimulate cAMP formation in CHO/hPTHR or parental CHO cells[1].
|
---|---|
ln Vivo |
Thirty minutes after delivery, SUN B8155 (100 mg/kg; ip) significantly lowers the serum calcium content by about 9%. Serum calcium levels are also lowered by human CT in a dose-dependent manner at 30 and 60 minutes (0.1 and 0.3 μg/kg) following administration[1].
|
References |
Molecular Formula |
C14H15N3O3
|
---|---|
Molecular Weight |
273.29
|
Exact Mass |
273.111
|
CAS # |
345893-91-6
|
PubChem CID |
135484493
|
Appearance |
Light yellow to yellow solid powder
|
Density |
1.34g/cm3
|
Boiling Point |
419ºC at 760 mmHg
|
Flash Point |
207.2ºC
|
Index of Refraction |
1.637
|
LogP |
2.403
|
Hydrogen Bond Donor Count |
3
|
Hydrogen Bond Acceptor Count |
5
|
Rotatable Bond Count |
2
|
Heavy Atom Count |
20
|
Complexity |
508
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
SGJLINMLDNLWOS-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C14H15N3O3/c1-8-7-12(18)17(20)14(19)13(8)9(2)16-11-6-4-3-5-10(11)15/h3-7,19-20H,15H2,1-2H3
|
Chemical Name |
5-[N-(2-aminophenyl)-C-methylcarbonimidoyl]-1,6-dihydroxy-4-methylpyridin-2-one
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 100 mg/mL (365.91 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.6591 mL | 18.2956 mL | 36.5912 mL | |
5 mM | 0.7318 mL | 3.6591 mL | 7.3182 mL | |
10 mM | 0.3659 mL | 1.8296 mL | 3.6591 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.